News
Public · Published
Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latigo Biotherapeutics reported third-quarter 2026 results and said Phase 3 trials of onzotrigine remain on track to begin, with topline results expected in the second half of 2027. The company plans to add Percocet as a comparison arm and said its cash and equivalents are expected to fund operations into a later period.
Published:
Updated:
What happened
Latigo Biotherapeutics reported third-quarter 2026 results and said Phase 3 trials of onzotrigine remain on track to begin, with topline results expected in the second half of 2027. The company plans to add Percocet as a comparison arm and said its cash and equivalents are expected to fund operations into a later period.
Confirmed
Global impact / market context
The planned Percocet comparison could help Latigo assess onzotrigine against a commonly used opioid in a second surgical setting. If trial progress and results support the company’s plans, they could influence development spending and the path toward potential future sales; the article reports no results yet.
Analyst inference
For a clinical-stage drug developer, cash expected to cover operations provides time to conduct trials without relying immediately on new funding. Trial delays or unfavorable results could still increase costs or weaken investor confidence, while positive data could support the case for further development.
Analyst inference
What to watch
- Whether the Phase 3 bunionectomy and open-label safety trials of onzotrigine begin as planned, with topline results currently expected in the second half of 2027. Confirmed
- Whether Latigo adds Percocet, an opioid pain medicine, as the planned comparison arm in the Phase 3 bunionectomy trial. Proposed
- Whether the ongoing Phase 2 LTG-321 chronic-pain trial produces topline results in the second half of 2027, as the company expects. Confirmed